Focusing on Change, Collaborating for Win-Win Results | Wanbangde Pharmaceutical Group Exhibits at the 89th National Pharmaceutical Fair

From November 20 to 22, 2024, a grand annual "feast" of the pharmaceutical industry—the three-day National Pharmaceutical Trade Fair—successfully concluded at the Wuhan International Expo Center.

Wanbangde Pharmaceutical Group appeared at this year's Pharmaceutical Trade Fair with a specially designed booth. The booth continued the company's previous style, focusing on simplicity and elegance, with the main color scheme consistent with the company's logo, becoming an eye-catching highlight of the exhibition. Customers visiting the booth came in a steady stream. The Wanbangde Pharmaceutical Group sales team warmly and professionally welcomed guests from all directions, providing detailed introductions to Wanbangde's strategic layout and product advantages in multiple fields including cardiovascular and cerebrovascular, neurology, male ED, digestive and metabolic systems, and respiratory systems, and deeply analyzed its broad market potential. Through in-depth explanations and exchanges at the trade fair, customers gained a profound understanding of Wanbangde Pharmaceutical Group's product quality, product layout, and product variety.

This Pharmaceutical Trade Fair was not only a platform for Wanbangde Pharmaceutical Group to showcase its corporate strength and quality services but also a significant opportunity to promote the exchange of ideas and cooperation. In the future, Wanbangde Pharmaceutical Group will continue to uphold the corporate spirit of "pragmatism, innovation, quality, and efficiency," practice the mission of "pioneering innovation and caring for life," and strive to build Wanbangde Pharmaceutical Group into a benchmark enterprise in China's health industry.

Coinciding with the grand pharmaceutical trade event and the gathering of new and old friends from across the country, our company held a product promotion meeting and customer appreciation dinner themed "Joining Forces to Embrace Change and Win-Win Cooperation," attended by more than 100 customers. The appreciation meeting introduced three major themes: the company's marketing platform construction, future R&D layout, and core and upcoming products. It also focused on the company's core product lines in cardiovascular and neurological systems, laying out multiple new drug series including Huperzine A controlled-release tablets, Class 1 traditional Chinese medicine new drug projects, and WP203A related new drug projects, preparing for the sustainable development of the company's product lines.

Finally, the company's chairman, Zhao Shouming, delivered an important speech themed "Joining Hands at the Pharmaceutical Trade Fair to Unite and Create Brilliance," presenting the company's future development plans to all guests present and expressing the determination to advance hand in hand with everyone.

This appreciation meeting marks a new starting point for Wanbangde Pharmaceutical Group to unite the strength of partners and jointly embrace industry changes. Wanbangde Pharmaceutical Group will advance alongside industry partners, working together to contribute to the rapid development of China's pharmaceutical and health industry.

1. New ED product Xingfujian® Sildenafil Citrate Oral Suspension (import agency)

Treatment product in the ED field! Precise love anytime, anywhere! Industry category benchmark: precise dose control with oral spray; imported original research formulation: original imported quality, high quality, trustworthy.

2. Fujian® Butylscopolamine Bromide Injection

Highly selective peripheral anticholinergic drug that does not cross the blood-brain barrier, a national medical insurance product.

3. Fuweijian® Aluminum Magnesium Carbonate Chewable Tablets

National medical insurance, national essential medicine, consistency evaluation.

4. Fujian® Tenofovir Disoproxil Fumarate Tablets

National medical insurance, consistency evaluation approved variety, a new nucleotide reverse transcriptase inhibitor! Low toxicity, low drug resistance, first-line treatment drug for chronic hepatitis B antiviral therapy!

5. Cardiovascular and cerebrovascular line: Ginkgo Leaf Dropping Pills, Gynostemma Pentaphyllum Total Saponins Granules

6. Neurological system line: Huperzine A Injection

7. Respiratory system line: Bromhexine Hydrochloride Injection, Bromhexine Hydrochloride Tablets, Pediatric Paracetamol and Chlorpheniramine Granules

8. Digestive system line: Metronidazole Injection

9. Psychiatric system line: Chlorpromazine Hydrochloride Tablets, Clozapine Tablets

10. Antibiotic line: Levofloxacin Tablets, Cefaclor Granules, Cefixime Tablets, Artificial Calculus Bovis Metronidazole Capsules

11. Other product lines: Biphenyl Dimethyl Dicarboxylate Dropping Pills, Calcium Citrate Tablets, Flunarizine Hydrochloride Capsules